Daiichi reports Phase IIIb data for edoxaban in cancer-associated VTE

Daiichi Sankyo Co. Ltd. (Tokyo:4568) said once-daily oral edoxaban (DU-176b) met the primary endpoint of non-inferiority to standard of care (SOC) dalteparin in

Read the full 239 word article

User Sign In